Get the Stockscreener App
0.189
10.68%
-0.0226
Processa Pharmaceuticals Inc stock is traded at $0.189, with a volume of 3.65M.
It is down -10.68% in the last 24 hours and down -13.93% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.2116
Open:
$0.2037
24h Volume:
3.65M
Relative Volume:
0.20
Market Cap:
$9.52M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.0392
EPS:
-4.82
Net Cash Flow:
$-11.12M
1W Performance:
-13.30%
1M Performance:
-13.93%
6M Performance:
-64.92%
1Y Performance:
-86.40%
1-Day Range:
$0.181
$0.2044
1-Week Range:
$0.181
$0.23
52-Week Range:
$0.15
$1.50
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.189 | 10.65M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Applying Elliott Wave Theory to Processa Pharmaceuticals Inc.2025 Earnings Impact & Reliable Price Action Trade Plans - Newser
What’s the recovery path for long term holders of Processa Pharmaceuticals Inc.Market Sentiment Report & Verified Swing Trading Watchlist - Newser
Historical volatility pattern of Processa Pharmaceuticals Inc. visualizedDay Trade & Precise Buy Zone Tips - Newser
Published on: 2025-08-31 19:29:49 - Newser
Real time breakdown of Processa Pharmaceuticals Inc. stock performanceJuly 2025 Levels & Real-Time Stock Movement Alerts - Newser
Full technical analysis of Processa Pharmaceuticals Inc. stockJuly 2025 Fed Impact & Free Verified High Yield Trade Plans - Newser
How Processa Pharmaceuticals Inc. stock performs during market volatilityWeekly Gains Summary & Weekly Breakout Stock Alerts - Newser
Analyzing drawdowns of Processa Pharmaceuticals Inc. with statistical toolsJuly 2025 Selloffs & Risk Controlled Daily Plans - Newser
Combining machine learning predictions for Processa Pharmaceuticals Inc.2025 Analyst Calls & Low Risk High Reward Ideas - Newser
Processa Pharmaceuticals Inc. Reaches Critical Trendline Support2025 Volume Leaders & Growth Oriented Trade Recommendations - beatles.ru
Can momentum traders help lift Processa Pharmaceuticals Inc.Earnings Risk Report & Weekly Watchlist for Consistent Profits - Newser
Using Python tools to backtest Processa Pharmaceuticals Inc. strategiesMarket Growth Summary & AI Forecast for Swing Trade Picks - Newser
How hedge fund analytics apply to Processa Pharmaceuticals Inc. stockWeekly Gains Report & Daily Profit Focused Screening - Newser
Published on: 2025-08-30 21:18:23 - Newser
Is Processa Pharmaceuticals Inc. a candidate for recovery playQuarterly Earnings Report & Low Risk High Reward Trade Ideas - Newser
Processa Pharmaceuticals Inc. stock retracement – recovery analysisWeekly Investment Recap & Expert Curated Trade Ideas - Newser
What’s the recovery path for long term holders of Processa Pharmaceuticals IncShare Buyback & Free Daily Entry Point Trade Alerts - Newser
Are Bears Losing Grip on Processa Pharmaceuticals Inc. getLinesFromResByArray error: size == 0 - newsyoung.net
Will Processa Pharmaceuticals Inc. price bounce be sustainable2025 Key Lessons & Weekly Top Gainers Trade List - Newser
Chart based analysis of Processa Pharmaceuticals Inc. trendsJuly 2025 Levels & Precise Buy Zone Identification - Newser
How to use a screener to detect Processa Pharmaceuticals Inc. breakoutsWeekly Trade Report & Verified Technical Trade Signals - Newser
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jan 27 '25 |
Buy |
0.80 |
87,200 |
69,542 |
87,200 |
| Young David | Pres. Research & Development |
Jan 27 '25 |
Buy |
0.80 |
124,500 |
99,289 |
205,405 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 27 '25 |
Buy |
0.80 |
43,500 |
34,691 |
43,500 |
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):